Results 11 to 20 of about 2,398,894 (298)

Antibody drug conjugates [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +2 more sources

Antibody–Drug Conjugate to Treat Meningiomas

Pharmaceuticals, 2021
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control ...
Kai Chen, Yingnan Si, Jianfa Ou, Jia-Shiung Guan, Seulhee Kim, Patrick Ernst, Ya Zhang, Lufang Zhou, Xiaosi Han, Xiaoguang (Margaret) Liu   +9 more
doaj   +3 more sources

An Immunosuppressive Antibody–Drug Conjugate [PDF]

Journal of the American Chemical Society, 2015
We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E, Liu, Tao, Wang, Ying, Cao, Yu, Du, Jintang, Luo, Xiaozhou, Deshmukh, Vishal, Kim, Chan Hyuk, Lawson, Brian R, Tremblay, Matthew S, Young, Travis S, Kazane, Stephanie A, Wang, Feng, Schultz, Peter G   +13 more
openaire   +6 more sources

Applications of Pharmacometrics in Antibody–Drug Conjugate Development [PDF]

Pharmaceutics
Antibody–drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy.
Xiaoliang Cheng, Shuangmin Ji, Yonghyun Lee, Haiyan Dong   +3 more
doaj   +2 more sources

Exploration of the antibody–drug conjugate clinical landscape

mAbs, 2023
The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 years. In November 2022, ElahereTM became the latest ADC to be approved by the US Food and
Heather Maecker, Vidya Jonnalagadda, Sunil Bhakta, Vasu Jammalamadaka, Jagath R. Junutula   +4 more
doaj   +3 more sources

CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL [PDF]

Cells
Transcriptomic analyses of public datasets (TCGA and GTEx) revealed that both CD74 and Cathepsin L (CTSL) are significantly overexpressed in diffuse large B-cell lymphoma (DLBCL) compared to normal tissues, and that their expression levels are highly ...
Ihab Abd-Elrahman, Noha Khairi, Reut Sinai-Turyansky, Ivan Zlotber, Riki Perlman, Emmanuelle Merquiol, Galia Blum, Dina Ben Yehuda   +7 more
doaj   +2 more sources

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]

Cancer Medicine
Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg   +5 more
doaj   +2 more sources

Novel Immune Checkpoint Inhibitor and Antibody–Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer [PDF]

Current Oncology
Immune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier
Joseph Vento, Tian Zhang, Yair Lotan, Solomon Woldu, Qian Qin   +4 more
doaj   +2 more sources

Antibody–Drug Conjugates [PDF]

Bioconjugate Chemistry, 2015
Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Li, Peng, Xiaoyuan, Chen
openaire   +5 more sources

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production [PDF]

, 2023
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community.
Muneki, Isokawa, Sayaka, Kawaguchi, Tatsuya, Okuzumi, Yuri, Ooba, Rika, Takasugi, Yutaka, Matsuda, Natsuki, Shikida, Kazutaka, Shimbo, Tomohiro, Fujii, Tomohiro, Watanabe, Akira, Nakayama, Kei, Yamada, Takuya, Seki, Yusuke, Iwai, Noriko, Hatada, Brian. A., Mendelsohn, Kazutoshi, Takahashi   +16 more
core   +2 more sources